The five-year contract, which began September 2017 and is worth up to $9.5m, was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Vince & Associates Clinical Research, an Altasciences company, is an early phase contract research organization (CRO) headquartered in Overland Park, KS.
According to the company, it will conduct clinical pharmacology studies to support the development of new medications for the treatment of substance use disorders.
The company was previously awarded approximately $4m by the NIDA as part of a multi-year contract that ran from 2012 to 2017.
In October, Amygdala Neurosciences Inc. contracted Vince & Associates to conduct a Phase Ib alcohol interaction study of ANS-667 also for the treatment of substance abuse.